Vinay Prasad has made a surprising return to the FDA just weeks after his ouster, a move that has garnered significant attention amidst a backdrop of political shifts and industry challenges. Following his controversial tenure and the subsequent calls for his reinstatement from various quarters, including FDA leadership and industry analysts, Prasad resumes his leadership role overseeing vaccine and gene therapy programs. His brief exit sparked discussions about the intersection of politics and regulatory practices in the biomedical field, particularly as the FDA navigates a complex landscape marked by pressures from both the biotech sector and political factions. Industry observers speculate on the implications of this shakeup for companies like Sarepta and the future of regulatory governance.